Kiniksa Pharmaceuticals International (KNSA) Price to Sales (2021 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Price to Sales for 6 consecutive years, with 40.95 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 56.66% year-over-year to 40.95; the trailing twelve-month figure through Jun 2026 stood at 11.86 (up 53.22% YoY), and the FY2025 full-year result was 9.3, up 37.03% from the prior year.
• Price to Sales rose to 40.95 in Q2 2026 per KNSA's latest filing, from 34.52 in the prior quarter.
• Across five years, Price to Sales topped out at 49.9 in Q2 2022 and bottomed at 18.01 in Q3 2022.
• Historically, Price to Sales has averaged 31.79 across 5 years, with a median of 31.67 in 2024.
• The sharpest annual moves came in 2022 and 2023: Price to Sales slumped 86.12% in 2022, then surged 102.36% in 2023.
• Over 5 years, Price to Sales stood at 33.76 in 2022, then slipped by 12.1% to 29.67 in 2023, then dropped by 20.96% to 23.45 in 2024, then surged by 32.99% to 31.19 in 2025, then surged by 31.31% to 40.95 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 40.95, 34.52, and 31.19 for Q2 2026, Q1 2026, and Q4 2025 respectively.